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SUMMARY
Background: Seroepidemiological, pathological and animal studies suggest that chronic infection with Chlamy-
dia pneumoniae (Cp) may directly impact the development or progression of atherosclerosis and coronary heart
disease. The aim of the present study was to determine the seroprevalence of Cp infection and markers of syste-
mic inflammation in patients undergoing routine coronary artery examination and prior to heart revasculariza-
tion.
Material and methods: The research involved 76 patients with severe CAD and 81 control patients with normal
coronary circulation confirmed by coronary angiography. The presence of serum IgG and IgA antibodies to Cp
and plasma interleukin-8 (IL-8) levels was measured by EIA test. Furthermore, the levels of plasma C-reactive
protein, fibrinogen, total cholesterol, and triglycerides were measured in all patients.
Results: Seropositivity to Cp was found in 60.5% for IgG and in 61.8% of cases for IgA with CAD patients, as
compared to 26.0% and 29.5% in the controls (p<0.001), respectively. The levels of Interleukin-8, plasma fi-
brinogen, total cholesterol and triglycerides were significantly higher (p<0.001) in the CAD group, while C-re-
active protein tended to have a higher value in patients with atherosclerosis than in the control group, although
the difference was not significant.
Conclusions: Cp infection significantly increases the risk of CAD, usually requiring coronary bypass surgery or
percutaneous coronary intervention as effective measures. It may also modify the levels of serum lipids, CRP
and fibrinogen, increasing the risk of atherosclerosis. The strong correlation between the elevated IgG and IgA
titers of Cp in patients treated with angioplasty or surgery may impact their follow-up; this issue requires further
investigation.
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BACKGROUND
Several studies recently reported an association be-
tween coronary heart disease and certain persistent
bacterial and viral agents, including herpes viruses,
cytomegalovirus, coxackie B4 virus, Helicobacter
pylori (Hp) and Chlamydia pneumoniae [1–10].
Chlamydia pneumoniae (Cp) is an obligate, intra-
cellular pathogen and a common cause of benign
respiratory symptoms [11–15]. In most studies Cp
is the third most common cause of pneumonia.
Studies on antibody prevalence indicate a worl-
dwide incidence of pneumonia, and in some co-
untries even higher than 50% of the adult popula-
tion [16]. Cp usually causes around 6–10% of cases
of community-acquired pneumonia [17,18]. Du-
ring epidemics it may account for up to 50% of
such infections [19].
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Infection is predominantly linked with several
chronic inflammatory conditions, especially coro-
nary artery disease (CAD) and atherosclerosis. An
association between chlamydial infection and va-
scular disease was first reported in 1988 [20]. The
additional evidence that has accumulated since the
late 1980s from seroepidemiological, pathological
and animal studies suggests that Cp may directly
impact the development or progression of athero-
sclerosis and CAD.
The association between Cp and atherosclerosis
is based on evidence derived from the tissue
examination of arterial plaque material [19], and
has also been demonstrated in atherectomy spe-
cimens originating from patients with angina,
and the atheromatous arteries of patients with
other vascular diseases. In recent studies Cp has
been detected using PCR (polymerase chain re-
action) for the assessment of Cp genomic deoxy-
ribonucleic acid (DNA) and immunocytochemi-
stry, in a greater proportion of coronary athero-
matous lesions, and less frequently in other tis-
sues [20–22].
The presence of Cp within coronary atheroma
suggests that this respiratory pathogen is probably
conveyed from the lungs to the cardiac tissue be-
fore the infection of the cellular components of
the coronary arteries occurs [23]. Monocytes and
macrophages may carry the bacteria along from
the respiratory tract to the coronary arteries. Sub-
sequent direct endothelial damage caused by
a chronic infection of the endothelium in a gene-
tically predisposed individual may lead to the for-
mation and progression of atherosclerotic lesions.
Alternatively, the Cp-infected macrophages arri-
ving at the already-formed plaque lesions may be-
come activated and then perpetuate the various
inflammatory and procoagulant processes essen-
tial to atherothrombosis. Subsequent plaque in-
stability may lead to adverse cardiovascular
events, e.g. acute coronary syndromes, or cardiac
death.
The aim of the present study was to determine the
seroprevalence of Cp infection (Cp antibodies IgG
and IgA) and the presence of non-specific inflam-
mation markers, such as proinflamatory cytokines
(IL-8), as well as alterations in plasma C-reactive
protein, fibrinogen, cholesterol and triglycerides in
patients undergoing routine coronary angiography
prior to being referred to percutaneous coronary
intervention (PCI) or coronary artery by-pass gra-
fting (CABG).
MATERIAL AND METHODS
Two groups of patients (A and B) were studied.
Group A consisted of 76 patients with coronary ar-
tery disease (CAD), median age 54 years, age range
from 40 to 68, admitted to the Department of Car-
diac and Vascular Diseases. Their condition was
evaluated using clinical history, physical examina-
tion, EKG, maximum stress test, and cardiac coro-
nary angiography according to the Judkins techni-
que. Group B consisted of 81 controls, matched by
age, gender, and socioeconomic status, who were
also examined in the same way in the Cardiology
Unit, but had negative cardiac angiography; CAD
was ruled out in all of them as well. None of the
controls had previously suffered a myocardial in-
fraction. All of them produced negative stress test
results, although they were diagnosed with various
types of arrhythmia, hypertension, or chest discom-
fort with normal coronary arteries.
Coronary artery disease in the Group A patients,
confirmed angiographically, was diagnosed whene-
ver at least 70% stenosis was encountered in one
or more coronary arteries, or at least 50% stenosis
in the left main coronary artery. Previous myocar-
dial infarction was recognized in 31 patients (40%),
unstable angina in 15 patients (20%), and hyper-
tension in 48 patients (63%). Percutaneous corona-
ry intervention, including stent implantation and
directional atherectomy (DCA), was carried out in
48 patients (63%); 23 patients (30%), however,
were referred for CABG. Five patients were disqu-
alified from PCI or CABG due to multiple coronary
lesions, or the small dimensions of the coronary
vessels.
Maximum stress test
Exercise on the treadmill combined with electro-
cardiography (exercise stress testing) is important in
the diagnosis of angina pectoris. The purpose of
this exercise stress testing is to document the EKG,
blood pressure and symptomatic response to a gra-
dual increase in exercise, with constant EKG and
blood pressure monitoring for as long as the pa-
tient can tolerate this exercise. The stress test exer-
cise procedure is stopped at a predetermined heart
rate, typically 85% of the maximum, based on the
patient’s age. The stress test is considered negative
when a patient experiences no episodes of chest
discomfort and no change in EKG horizontal or do-
wnsloping ST segment with 1 mm depression or
greater after reaching the target heart rate. A positi-
ve stress test is defined by chest pain and/or ST
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segment depression during exercise, suggesting si-
gnificant myocardial ischemia.
Coronary angiography and ventriculography
Coronary angiography was carried out using the
Judkins technique. The right and left coronary arte-
ries were intubated by right and left Judkins 6F ca-
theters. A minimum of two projections of the right
coronary artery and four views of the left coronary
artery were obtained. The left ventricle angiogram
was done in RAO projection for the best visualiza-
tion of ventricle contraction. The percentage of le-
sion stenosis in the coronary arteries was evaluated
by the computerized quantitative coronary analysis
(QCA).
Determination of IgG and IgA antibodies against
Chlamydia pneumoniae by enzyme immunoassay
(EIA)
Blood samples were taken under basal conditions
and the serum subjected to serological analysis.
The Cp infection status was assessed by determi-
ning the IgG and IgA antibodies against Cp, using
a quantitative test, the ImmunoComb Chlamydia
Bivalent IgG and IgA Kit (Orgenics Ltd, France). An
IgG titer of greater than or equal to 1/32 and an
IgA titer of greater than or equal to 1/8 were consi-
dered positive.
Determination of plasma interleukin (IL-8) 
concentration
Plasma IL-8 was measured by an ELISA test using
kits supplied by Biosource Europe S.A. (Belgium),
and assaying the IL-8 level according to the manu-
facturer’s instructions.
Examination of plasma C-reactive protein (CRP)
C-reactive protein was detected by the latex agglu-
tination test (CRP – Slidex, bioMerieux, France). 50
µl of serum sample was mixed with 50 µl anti-CRP
latex reagent. The reaction was considered positive
when a distinct agglutination occurred within 3–5
minutes after mixing a serum sample with the anti-
-CRP latex reagent. The reaction was positive at
CRP concentrations of 20–600 mg/l.
Determination of plasma fibrinogen, cholesterol and
triglycerides
Plasma fibrinogen was measured by the Clauss
thrombin time method (Thrombin Reagent, Baxter,
Dade Division, Miami, Florida) with an STA analy-
zer. The normal range was 1.7 to 3.7 g/L. The inter
and intra-assay coefficient of variation was less
than 5% for fibrinogen measurements.
The serum concentrations of cholesterol and trigly-
cerides were determined enzymatically by routine
laboratory enzymatic methods [24].
Immunofluorescence staining of atheromatous
plaques from human coronary artery for confir-
mation of Cp presence
Arterial samples – plaque fragments from the left
arterial descending artery (LAD) – were taken du-
ring a direct coronary atherectomy using the Simp-
son technique [25], and were prepared in the ope-
rating theatre under sterile conditions. Two to four
specimens were dissected into ca. 2 mm slices and
then immersed in liquid nitrogen for further inve-
stigation.
For purposes of immunofluorescence, the frozen
specimens were cut by cryostat at 5 µm, air-dried
and stored in acetone. The slides were then labe-
led with a C. pneumoniae detection kit (DAKO, K-
-6601) and reviewed in a laser scanning confocal
microscope (OLYMPUS Fluoview) fitted out with
argon laser and a filter combination of multi-band
path filters for detecting FITS emission. Positive
controls were provided by the specimens supplied
with the immunodetection kit. Autopsy specimens
taken from tissue without atheromatic lesions were
used as negative controls. The green apple fluore-
scence of Cp elementary body was detected and
recorded as a computer file in TIFF format.
Statistical analysis
The paired Student t-test was used to assess the
differences between groups. With respect to all
analyzed variables the level of statistical significan-
ce was set at p<0.05. The OR test (OR; 95% confi-
dence interval) was used to assess the correlation
between the presence of anti-Cp IgG and IgA anti-
bodies and coronary heart disease.
RESULTS
Table 1 shows the number of patients and age di-
stribution of both the CAD and control groups, as
well as the percentage of positive results regarding
the presence of anti-Cp IgG and IgA and increased
levels of IL-8, CRP, fibrinogen, cholesterol and tri-
glycerides. These data demonstrate that both the
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CAD patients and the controls were well matched
in terms of age, and that there was a significant dif-
ference in the overall prevalence of serum IgG and
IgA, IL-8, fibrinogen, cholesterol and triglycerides
between the CAD patients and the controls.
The presence of Cp infection was significantly hi-
gher in Group A patients with CAD than in the he-
althy controls without CAD (Group B). Seropositivi-
ty to Cp was found in 60.5% of the CAD patients
for IgG, and in 61.8% for IgA, as opposed to 26.0%
and 29.5% respectively among the healthy controls.
The odds ratio (OR) in patients with CAD was (IgG;
OR=4.4; 95% CI 2.23–8.6; p<0.001) and (IgA;
OR=3.8; 95% CI 1.7–8.5 p<0.001) (Fig. 1,2).
IL-8 concentration proved to be positively correla-
ted with CAD. The median plasma levels of IL-8 in
patients with CAD was significantly higher than in
the controls (40.5 pg/ml vs. 0.9 pg/ml, p<0.001).
The total plasma cholesterol concentration and tri-
glycerides had higher values in patients with CAD
than in the controls (241±35 mg/dl for cholesterol
and 206±24 mg/dl for triglycerides in the CAD pa-
tients, vs. 192±22 mg/dl and 170±35 mg/dl, re-
spectively); the difference between the CAD pa-
tients and the controls in these parameters reached
a high level of statistical significance (p<0.001).
C-reactive protein (CRP) levels were also higher in
patients with CAD compared to the controls
(20–200 mg/l vs. 7–200mg/l). This was associated
with higher serum fibrinogen in the CAD patients
than in the controls (3.5±1.2 g/l vs. 2.8±0.9 g/l).
These differences were also highly statistically signi-
ficant (p<0.001).
The specimens extracted by direct atherectomy
from patients diagnosed with severe atherosclerosis
in the left descending coronary artery proved to be
reactive for chlamydia in direct immunofluorescen-
ce. An example of immunofluorescence reactivity
to Cp in a case of severe atherosclerosis is shown
in Fig. 3.
DISCUSSION
Higher arterial blood pressure, elevated serum
cholesterol and smoking are considered the major
risk factors in the development of atherosclerosis
and coronary heart disease. Furthermore, age, sex,
obesity, diabetes, high serum triglyceride count
and low high-density lipoprotein (HDL) levels are
factors predisposing to CAD. Recent studies have
also shown that slightly elevated C-reactive protein
(CRP) concentration in serum is a marker of syste-
mic inflammation [26]. Fibrinogen is an acute-pha-
se protein that acts as a cofactor in platelet aggre-
gation. Elevated fibrinogen levels are associated
with an increased risk of CAD, due to the effect on
platelet aggregation, blood viscosity, vascular per-
meability and leukocyte chemotaxis.
It is also believed that Cp infections are associated
with elevated fibrinogen levels [27]. The concentra-
tion of CRP correlates directly with the incidence
No Age IgG anti Cp IgA anti Cp CRP [mg/l] IL-8 [pg/ml] Fibrinogen [g/l] Cholesterol[mg/dl]
Triglycerides
[mg/dl]
pts with CAD
pts without CAD
p
76
81
54 (40-68)
55 (38-70)
NS
46 (60.5%)
21(26%)
<0.001
47 (61.8%)
29.5 (29.5%)
<0.001
20-200
7-200
–
40.5± 3
0.9±0.1
<0.001
3.5 ±1.2
2.8±0.9
<0.001
241±35
192±22
<0.001
206±24
170±35
<0.001
Table 1. Evaluated parameters in the CAD and control groups.
Figure 1. Seropositivity Chlamydia pneumoniae IgG and CAD.
Figure 2. Seropositivity Chlamydia pneumoniae IgA and CAD.
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and severity of coronary, cerebral and peripheral
atherosclerosis. Although CRP may be a useful in-
flammation marker, its usefulness is by no means li-
mited to artherosclerosis. Cp infection may induce
chronic immune activation (mediated by cytokines,
such as interleukin 1, 6, 8 and TNF-α) that contri-
butes to direct chronic endothelial cell damage, or
stimulates the synthesis of acute phase proteins,
such as fibrinogen and C-reactive protein [28–30].
Cytokines that participate in inflammatory reac-
tions [31] are also known to influence lipid meta-
bolism. Tumor necrosis factor-α and IL-1, which
are also produced in Cp infections, may inhibit li-
poprotein lipase, leading to the mobilization of li-
pids from tissues and to increased serum triglyceri-
de levels and lower HDL cholesterol concentra-
tion. Cp is a gram-negative intracellular bacterium
possessing lipopolysaccharides (LPS) as a major
constituent of its outer membrane. Its multiplica-
tion is associated with cytokine production and the
induction of adhesion, although chlamydial LPS
has lower endotoxin activity than e. g. enterobac-
terial LPS [32].
Cp’s life cycle causes chronic infection. Chronic in-
fection can lead to elevated levels of CRP, leucocy-
tes and several cytokines; all associated with arte-
riosclerosis. Several studies have shown that chla-
mydia germs are encountered in macrophages in
a high proportion of atherosclerotic plaques. The
production of TNFα and IL-1, IL-6, and other sub-
stances may damage the intima and lead to plaque
rupture. A variety of techniques, including immu-
nocytochemistry, PCR, electron microscopy and
bacterial culture, have been used to confirm the
incidence of Cp in human atherosclerotic speci-
mens.
The present study confirmed the incidence of Cp
in atherosclerosis lesions by immunofloorescence
and laser scanning confocal microscopy. Positive
atherectomy specimens were found in young pa-
tients with short histories of CAD. Muhlestein et al.
[33] detected Cp in 79% of atherectomy speci-
mens, compared with 4% of non-atherosclerotic
arteries. The activation of inflammation and a local
immune response in the coronary arteries may in
some patients be in fact a response to an infection.
Figure 3. a) Frozen section of coronary atherectomy plaque reacted with antibody FITC-labelled against Chlamydia pneumoniae antigen, as observed
using laser confocal scanning microscopy (OLYMPUS Fluoview). A large number of green apple fluorescence staining C. pneumoniae
elementary bodies were encountered. b) Higher magnification of Photograph A. The diameter of chlamydial elementary body aggregates in
app. 5 µm. c) Cross-section of specimen A. The chlamydial elementary body is located inside the plaque.
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The present study showed a high prevalence of Cp
infection in patients treated by PCI or CABG. The-
re are very few studies focusing on the follow-up
period in patients with Cp infections, treated either
by surgery or angioplasty.
Bartels et al. [34] assessed the occluded vein grafts
taken from 45 patients subjected to repeat bypass
surgery. A strong correlation between elevated IgG
titers and the detection of Cp was established. Re-
cently Tiran and associates [35] suggested that the
PCI-induced stimulation of the humoral response
to Cp after manipulation in atherosclerotic plaqu-
es, or in the ascending aorta, may actually be the
reason for the elevation of anti-Cp antibodies. Fur-
ther studies should therefore investigate whether
patients undergoing PCI or CABG could profit from
antibiotic therapy.
Similar findings regarding strong correlation between
Cp IgG and IgA titers and the incidence of coronary
heart disease [1,26,33] may be encountered in the li-
terature, although several publications have claimed
that there is no evidence for such correlation whatso-
ever [36–38]. One of the likely causes for such highly
contradictory results is that the respective investiga-
tors may have used different serologic techniques,
and also applied diverse criteria for discriminating
between chronic and acute Cp infection.
The measurement of markers of systemic inflamma-
tion can be helpful in this strategy. In the present stu-
dy, IL-8 and fibrinogen were significantly higher in
the CAD group, compared to the control group. The
slightly elevated CRP in Group A (with atherosclero-
sis) can only be explained by the common use of
aspirin by patients prior to their hospital admission.
Although it has long been commonly acknowled-
ged that serology constitutes an important diagno-
stic instrument in the assessment of chronic Cp in-
fection, some studies have focused exclusively on
assessing IgG or IgA, while others have based their
conclusions on either the presence or absence of
the circulating immune complex containing Cp
LPS. The high prevalence of seropositive cases en-
countered in the general population probably re-
flects the incidence of the infection itself and the
actual duration of elevated antibody titers follo-
wing infection. It is therefore difficult to establish
whether seropositivity to Cp indicates a chronic,
active infection, or simply reflects a past exposure.
An accurate diagnosis of active infection would re-
quire repeated sampling of serum, with a view to-
ward testing for elevated antibody titters.
The vast majority of the patients we studied had
long suffered from stable angina, hence their expo-
sure to Cp infection was in fact quite considerable.
It would be both scientifically challenging, as well
as of tangible benefit to the patients, to establish
whether Cp infection in patients with acute coro-
nary syndrome is a common occurrence, and if so,
whether sustained antibiotic therapy could then
advantageously impact their long-term prognosis.
CONCLUSIONS
1. The present data confirm the presence of Cp
bacteria in the arterial wall using immunocyto-
chemistry.
2. Cp infection significantly increases the risk of co-
ronary artery disease possibly require revascula-
rization.
3. Cp infection seems to modify serum lipids, CRP
and fibrinogen levels, which increase the risk of
severe coronary atherosclerosis.
4. Our results support the notion that the eradica-
tion of Cp may advantageously impact the pro-
gnosis for patients with coronary heart disease.
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